Kissei Pharmaceutical Co., Ltd. (KSPHF) Research

Kissei Pharmaceutical Co., Ltd. is a Japan-based enterprise primarily dedicated to the discovery, development, production, and commercialization of pharmaceutical products within the domestic market. Its current portfolio of marketed therapeutics addresses various medical conditions: Dysuria: Urief and Urief OD tablets. Type 2 Diabetes: Glufast, Glubes, and Marizev tablets. Renal Anemia: Injectable Darbepoetin Alfa BS and Epoetin Alfa BS. Overactive Bladder: Beova tablets. Hyperphosphatemia: P-TOL chewable tablets. Nocturia (stemming from nocturnal polyuria in males), Central Diabetes Insipidus, and Nocturnal Enuresis (due to diminished urine osmolality): Minirin Melt OD tablets. The company maintains an active development pipeline, featuring several promising candidates in advanced clinical stages: KPS-0373: Has successfully completed Phase III clinical trials for spinocerebellar ataxia. CCX168: Finished Phase III trials for microscopic polyangiitis and granulomatosis with polyangiitis. AJM300: Is currently undergoing Phase III clinical evaluation for ulcerative colitis. R788: Is in Phase III trials for chronic idiopathic thrombocytopenic purpura. MR13A9: Is progressing through Phase III clinical studies for uremic pruritus in dialysis patients. Further expanding its innovation efforts, Kissei is also advancing other compounds, including: KLH-2109: For endometriosis and uterine fibroids. KDT-3594: Aimed at Parkinson's disease. Silodosin: Targeting dysuria linked to benign prostatic hyperplasia. Mitiglinide: For type 2 diabetes mellitus. Bedoradrine: For the acute exacerbation of asthma. Beyond its core pharmaceutical operations, Kissei Pharmaceutical diversifies its business by developing and selling specialized nutritional products, such as protein-controlled and energy-supplying foods. It also handles the procurement and distribution of related materials. Additionally, the company offers a suite of services, including information system development and data processing, construction contracting, equipment and facility management, and support for information gathering and development. Founded in 1946, the company initially operated as Kissei Yakuhin Kogyo Co., Ltd., before rebranding to Kissei Pharmaceutical Co., Ltd. in October 1964. Its corporate headquarters are located in Matsumoto, Japan.

Open Kissei Pharmaceutical Co., Ltd. (KSPHF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.